Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

Juan Jaen

Terry Rosen

Arcus Biosciences, Inc.

Therini Bio develops immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. It focuses on a clinical-stage pipeline aimed at treating severe neurological and retinal diseases.

Therini Bio

Umoja Biopharma develops integrated platform therapeutics that reprogram the immune system to target cancer cells and generate lasting remissions.

Umoja Biopharma

Li Lab of Computational Cancer Immunology focuses on cancer research, particularly on the computational analysis of immune responses in cancer. The lab has conducted various studies related to T cell receptor repertoires, mitochondrial transfer between cells, and cancer immunotherapy.

Li Lab of Computational Cancer Immunology

Arcus Biosciences is a rapidly growing, clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines that may have the potential to help people with cancer live longer. Located in the San Francisco bay area, Arcus Biosciences offers a competitive compensation and benefits package, including aggressive participation in the growth of the company in the form of stock option grants. Arcus has an ambitious undertaking and expects to become a force in the discovery, development and commercialization of novel combination therapies to treat cancer in areas of high unmet need. Our employees enjoy operating in an exceptionally dynamic and team-driven environment in which the “rule book” has not yet been written.

Metric
Company Name	Arcus Biosciences, Inc.	Therini Bio	Umoja Biopharma	Li Lab of Computational Cancer Immunology
Symbol	RCUS
MSH ID	COM:ARCUSBIO	COM:THERINIBIO	COM:UMOJA-BIOPHARMA	ORG:LILAB-UTSW
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology	Biotechnology
Country	US	US	US	US
Stage
Employee Count	577
Website	arcusbio.com	therinibio.com	umoja-biopharma.com	lilab-utsw.org
LinkedIn	arcus-biosciences	therinibio
Founders

Metric
Market Cap	1.27B
Enterprise Value
Monthly Web Traffic	52.33K	6.83K
Web Traffic Growth	0.36	-0.19
Valuation
Raised Capital	150M

Metric
Revenue	117M
Revenue (LTM)
Revenue (NTM)
Gross Profit	101M
EBITDA	-291M
Operating Income	-340M
Net Income	-307M
EPS	-4.15
Diluted EPS	-4.15
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.96
Operating Profit Margin	-1.14
EBITDA Margin	-2.49
Net Profit Margin	-0.97
Return on Equity	-0.41
Return on Assets	-0.18
Return on Capital Employed	-0.25

COM:ARCUSBIO

Arcus Biosciences

Last Close

14.28

22/11 21:00

Market Cap

1.27B

Beta: -

Volume Today

534.33K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-3.90
P/B Ratio	2.19
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	13.00
EV Multiple	-5.15

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle	131.03
Cash Conversion Cycle	-256.79
Asset Turnover	0.21

Metric
Operating Cash Flow	-306M
Free Cash Flow	-330M
Cash Flow to Debt
Operating Cash Flow/Sales	-0.85
Free Cash Flow Yield	-0.27

Metric
Cash & Equivalents	127M
Accounts Receivable	15M
Inventory
Goodwill
Debt to Capitalization	0.21
Debt to Assets
Current Ratio	4.41
Quick Ratio	5.22

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.83
R&D to Revenue	3.79
SG&A to Revenue	1.34